Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma
A phase 2 trial of QLS32015, Pomalidomide, Dexamethasone in multiple myeloma, run by Qilu Pharmaceutical Co., Ltd., now recruiting.
Overview
Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma is a phase 2 interventional study registered as NCT07018050 by Qilu Pharmaceutical Co., Ltd., with 160 participants planned, started 2025-09-12 and due to reach its primary completion in 2027-11. Interventions recorded: QLS32015, Pomalidomide, Dexamethasone, QL2109 or Daratumumab, Bortezomib. Conditions listed: Relapsed or Refractory Multiple Myeloma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma
Shares QLS32015, Qilu Pharmaceutical, Multiple myeloma.
- TrialSelinexor and Backbone Treatments of Multiple Myeloma Patients
Shares Pomalidomide, Bortezomib, Dexamethasone, Lenalidomide.
- TrialAll Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myelo
Shares Pomalidomide, Bortezomib, Dexamethasone, Multiple myeloma.
- TrialA Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Re
Shares Pomalidomide, Bortezomib, Dexamethasone, Multiple myeloma.
- TrialA Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)
Shares Pomalidomide, Bortezomib, Dexamethasone, Multiple myeloma.
- TrialA Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With
Shares Pomalidomide, Bortezomib, Dexamethasone, Multiple myeloma.
- TrialA Study of Daratumumab
Shares Pomalidomide, Dexamethasone, Lenalidomide, Multiple myeloma.
- TrialA Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Mult
Shares Pomalidomide, Bortezomib, Dexamethasone, Multiple myeloma.